Total Funding
6
Total FundingSeries A raised
Growth Score
pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Zyngenia is a biotherapeutics company focused on the development of the next-generation of antibody-derived drugs.
Robert Garland: director
David Parkinson: Acting CEOPast Role: Nodality, President & CEO
About the Company
Founded in 2008, Zyngenia, Inc. is a privately held biotherapeutics company focused on the development of the next-generation of antibody-derived drugs. The company uses proprietary technology to enable the development of singular molecular entities that address two or more targets, by combining the activity of two or more biologic therapies into
one protein (known as a Zybody™). In addition, the technology will also be applied to drug targets that previously have not been reachable through the use of traditional, single specificity, monoclonal antibodies.
